Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Treace Medical Concepts (TMCI) EBIAT (2020 - 2026)

Treace Medical Concepts filings provide 6 years of EBIAT readings, the most recent being -$9.4 million for Q4 2025.

  • On a quarterly basis, EBIAT fell 1775.05% to -$9.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$59.0 million, a 5.85% decrease, with the full-year FY2025 number at -$59.0 million, down 5.85% from a year prior.
  • EBIAT hit -$9.4 million in Q4 2025 for Treace Medical Concepts, up from -$16.3 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of -$501000.0 in Q4 2024 to a low of -$21.2 million in Q2 2024.
  • Median EBIAT over the past 5 years was -$12.2 million (2022), compared with a mean of -$11.4 million.
  • Biggest five-year swings in EBIAT: skyrocketed 92.02% in 2024 and later crashed 1775.05% in 2025.
  • Treace Medical Concepts' EBIAT stood at -$6.6 million in 2021, then skyrocketed by 33.34% to -$4.4 million in 2022, then plummeted by 42.36% to -$6.3 million in 2023, then skyrocketed by 92.02% to -$501000.0 in 2024, then crashed by 1775.05% to -$9.4 million in 2025.
  • The last three reported values for EBIAT were -$9.4 million (Q4 2025), -$16.3 million (Q3 2025), and -$17.4 million (Q2 2025) per Business Quant data.